fr   en

Tableaux synoptiques (en anglais)

Parcourir par date
Rechercher par mot clé
Date: 2010-04-26
Acquiring pharma company: ALK-Abelló (Denmark)
Acquired biotech company: Fornix' Allergy Division, Artu Biologicals (The Netherlands)
Amount: € 19.6 million
Terms of the agreement: ALK-Abelló - Company Announcement
ALK and Fornix BioSciences have entered into an agreement to the effect that ALK proposes to acquire the Dutch activities of Fornix' Allergy Division, Artu Biologicals. This operation is part of ALK's strategy of expanding its global presence and of contributing to the consolidation of the allergy vaccine
industry. The proposed acquisition will strengthen ALK's market position in the Netherlands and give it a stronger platform for continued growth in its sales of GRAZAX® and other products.
Moreover, ALK will use its new market position to distribute coming tablet-based vaccines.
Artu's revenues in 2009 totalled € 26.1 million and operating profit (EBIT) totalled €12.5 million. Artu has 87 employees, about 45 of whom work in sales and marketing.
Other: The acquisition is subject to final approval by Fornix' shareholders. The
transaction is expected to become effective on July 1, 2010, after which Artu
and ALK's Dutch subsidiary will be fully integrated.